Market closedNon-fractional
Supernus Pharmaceuticals/SUPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Ticker
SUPN
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Rockville, United States
Employees
652
Website
www.supernus.com
SUPN Metrics
BasicAdvanced
$1.7B
Market cap
-
P/E ratio
-$0.31
EPS
1.01
Beta
-
Dividend rate
Price and volume
Market cap
$1.7B
Beta
1.01
Financial strength
Current ratio
1.73
Quick ratio
1.416
Long term debt to equity
3.551
Total debt to equity
4.534
Interest coverage (TTM)
6.18%
Management effectiveness
Return on assets (TTM)
0.23%
Return on equity (TTM)
-1.68%
Valuation
Price to revenue (TTM)
2.806
Price to book
1.81
Price to tangible book (TTM)
7.25
Price to free cash flow (TTM)
16.791
Growth
Revenue change (TTM)
-10.64%
Earnings per share change (TTM)
-133.85%
3-year revenue growth (CAGR)
2.40%
3-year earnings per share growth (CAGR)
-47.21%
What the Analysts think about SUPN
Analyst Ratings
Majority rating from 4 analysts.
SUPN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$144M
-12.60%
Net income
$100K
-90.91%
Profit margin
0.06%
-90.91%
SUPN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.49
$0.24
$0.89
$0.46
-
Expected
$0.07
$0.08
$0.55
$0.38
$0.39
Surprise
653.85%
200.00%
60.84%
22.12%
-
SUPN News
AllArticlesVideos
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
GlobeNewsWire·3 days ago
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals (SUPN) has a market cap of $1.7B as of July 27, 2024.
What is the P/E ratio for Supernus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 0 as of July 27, 2024.
Does Supernus Pharmaceuticals stock pay dividends?
No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Supernus Pharmaceuticals dividend payment date?
Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Supernus Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.